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Abstract
Background: Among patients with HIV infection, depression is the most frequently observed psychiatric disorder. The 
presence of depressive symptoms and cognitive dysfunction among HIV patients has not been well studied in Sub-
Saharan Africa. Initiation of highly active antiretroviral therapy (HAART) may have an effect on the prevalence and the 
change over time of depression symptoms and cognitive impairment among HIV-positive individuals.
Methods: We recruited 102 HIV-positive individuals at risk of cognitive impairment who were initiating HAART and 25 
HIV-negative individuals matched for age and education. Depression was assessed using the Centre for Epidemiologic 
Studies Depression Scale (CES-D). Neurocognitive assessment included the International HIV Dementia Scale (IHDS), an 
8 test neuropsychological battery and the Memorial Sloan Kettering scale. Assessments were carried out at 0, 3 and 6 
months.
Results: The HIV-positive group had more respondents with CES-D score > 16 than the HIV-negative group at all 3 
clinic visits (54%Vs 28%; 36% Vs 13%; and 30% Vs 24% respectively; all p < 0.050 OR 2.86, 95% CI: 1.03, 7.95, p = 0.044). 
The HIV positive group had higher likelihood for cognitive impairment (OR 8.88, 95% CI 2.64, 29.89, p < 0.001). A 
significant decrease in the mean scores on the CES-D (p = 0.002) and IHDS (p = 0.001) occurred more in the HIV-
positive group when compared to the HIV-negative group. There was no association between clinical Memorial Sloan 
Kettering score and depression symptoms (p = 0.310) at baseline.
Conclusion: Depression symptomatology is distinct and common among cognitively impaired HIV patients. Therefore 
individuals in HIV care should be screened and treated for depression.
Background
The World Health Organisation (WHO) estimates
depression to be the leading cause of disability as mea-
sured by Years Lost due to Disability (YLDs) contributing
to almost 12% of all disability [1,2]. It is the second lead-
ing contributor to the global burden of disease as mea-
sured by Disability Adjusted Life Years: DALYS (the sum
of years of potential life lost due to premature mortality
and the years of productive life lost) in the age category of
15 - 44 years for both sexes combined [3].
HIV is a highly prevalent condition in Uganda with a
current prevalence of 6% in the rural areas and 7% in the
urban areas [4]. Among patients with HIV infection, clin-
ical depression is the most frequently observed psychiat-
ric disorder, affecting between 4% and 14% of men and
women in some studies [5-7]. Indeed it has been noted
that depression symptomatology rises as AIDS progresses
[8]. Its rates are 2-3 times higher than those of the general
community [9]. Among recently diagnosed HIV patients
in South Africa the prevalence of major depression was
found to be 35% [10]. Another study using the Centre for
Epidemiologic Studies Depression Scale (CES-D) scale as
the screening tool and the Mini International Neuropsy-
chiatric Interview (MINI) as the diagnostic tool has
shown the rate of depression to be 14% among HIV-posi-
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Page 2 of 7tive individuals [11]. In Uganda, severe depressive symp-
tomatology using a cut off of > 23 among HIV-positive
individuals has been found at 47% using the CESD-
depression scale as the only investigative tool [12]. In the
same setting, rates for depression among first time
admissions of severe mental illness have been found at
10% [13]. While the rate in patients who are comorbid
with HIV and pulmonary tuberculosis has been found to
be 60% [14].
Psychiatric illness is not routinely screened for in
resource constrained settings and its symptoms are often
not easily recognised in the health care setting [3]. Com-
monly there are no units for mental health service deliv-
ery thus making depression often go undetected among
the HIV clientele that attend these clinics [12]. Secondly,
depressed patients lose hope and motivation and may
often neglect to take prescribed treatments, including
antiretroviral therapy.
Cognitive impairment in HIV patients occurs on a
spectrum ranging from minor cognitive motor disorder
to HIV dementia, (also known as AIDS dementia com-
plex, HIV encephalopathy and HIV associated dementia)
[15]. A study designed to assess the natural history of
HIV-associated affective and cognitive disorders found
the prevalence of cognitive impairment and prominent
depression symptomatology to be 17.9 and 15.5% respec-
tively [16]. Individuals that are depressed may or may not
show signs of cognitive dysfunction [15,17]. In some situ-
ations, depression may be the initial presentation of HIV
dementia and can make cognitive impairment worse [15].
Indeed the condition is at times difficult to differentiate
from HIV dementia [18]. This creates a situation in which
the depression often goes undetected and untreated in
many of the patients.
There is minimal epidemiological data analyzing men-
tal health outcomes among HIV-positive and HIV-nega-
tive individuals in the African setting. We therefore
undertook the following study whose aims were: (1) to
assess depression symptomatology among HIV-positive
patients who were about to initiate HAART and HIV-
negative individuals; (2) to determine the association of
depression symptomatology and cognitive function
among HIV-positive and HIV-negative individuals; and
(3) to evaluate changes in depression symptomatology
among HIV-positive individuals receiving HAART. Our
hypotheses were: (1) depression symptomatology would
occur more commonly among HIV-positive individuals
when compared to HIV-seronegative individuals; (2)
depression symptomatology would be associated with
cognitive impairment among HIV-positive individuals;
and (3) following initiation of HAART, depression symp-
tomatology would improve concomitant with improve-
ments in immunological function.
Methods
Ethical approval to carry out the study was received from
the Makerere University Research and Ethics Committee,
the Uganda National Council for Science and Technology
as well as the Institutional Review Board of the Johns
Hopkins University in Baltimore, Maryland. All study
participants gave informed consent. Individuals who
could read and write signed their names after reading
through the consent form. For individuals who were
unable to read, the research assistants read the form for
the individual who thereafter signed with the use of a
thumb print.
Participants
A prospective cohort of HIV-positive patients at risk for
cognitive impairment (as defined by a CD4 count < 200
or poor performance on a screening test for HIV demen-
tia [19]) and HIV-negative individuals was enrolled for
longitudinal assessment of depression symptomatology,
cognitive function and functional status. Between Sep-
tember 2005 and January 2007, we recruited 102 HIV-
positive individuals at the Infectious Disease Clinic, Mak-
erere University, located at Mulago national referral hos-
pital in Kampala, Uganda. This specialized outpatient
HIV clinic provides free quality care including anti-retro-
viral therapy for general HIV cases. It also serves as a
national referral centre, providing specialist consultations
for patients who are not responding well to treatment at
other health facilities. Over 10,000 HIV/AIDS clients
have been registered in the clinic since its establishment
in 2004. Approximately 5,600 of these clients receive life-
saving antiretroviral therapy. The 25 HIV-negative age-
and education-matched controls were recruited from the
AIDS Information Centre (AIC), a voluntary counselling
and testing centre. Selection criteria for the HIV positive
individuals included: CD4 lymphocyte count < 200, abil-
ity to speak Luganda or English, clinic attendance of ≥ 2
visits in the past 6 months, residence within a 20-km
radius of Kampala for the previous 6 to 12 months and
unlikely to move out of the area. The exclusion criteria
included age less than 18 years, an active or known past
central nervous system opportunistic infection, fever of >
37.5°C, a history of a chronic neurologic disorder, active
psychotic disorder, alcoholism - CAGE score of ≥2, physi-
cal deficit (e.g., amputation), a Karnofsky Performance
Scale < 50 or a severe medical illness that would interfere
with the ability to perform study evaluations. All above
applicable criteria were used for the HIV negative group.
There was no need for prior visits to the AIC in this
group however they were required to have an ELISA con-
firmed HIV negative test.
All HIV positive subjects had a baseline CD4 lympho-
cyte count, viral load and were initiated on the generic
co-formulated HAART regimen [Stavudine, lamivudine
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months.
Details of study design have been previously published
[20]. Specific elements used to answer our objectives are
described below.
Evaluation of depression
Clinical evaluation was carried out on all patients using
standardized questionnaires. Depression symptomatol-
ogy was assessed using the Centre for Epidemiologic
Studies Depression Scale, a widely used and well-vali-
dated instrument. This 20-item short, self-reporting scale
was developed by the Centre for Epidemiologic Studies
and has been validated and used in the African setting
[11,12,21]. It includes few vegetative symptoms, the
emphasis being on the affective symptoms like depressed
mood, feelings of guilt and worthlessness, psychomotor
retardation, loss of appetite and sleep disorders. A score
of at least 16 suggests a clinically significant level of psy-
chological distress. In a general population, approxi-
mately 20% of individuals would be expected to score in
this range. Individuals in our study with persistently high
scores on the CES-D during the follow up period were
referred to the psychiatric clinic for further management.
Evaluation of cognitive impairment
Cognitive assessment included a screening test for HIV
dementia using the International HIV dementia Scale
(IHDS) which was validated in the same study setting
previously [19]. The confirmatory cognitive tests were
performed using a battery of 8 neuropsychological tests
that included World Health Organization - University of
California-Los Angeles Auditory Verbal Learning Test
(WHO-UCLA AVLT) for verbal memory; Timed Gait
and Grooved Pegboard Tests for motor performance;
Symbol Digit Test and the Color Trails Test for psycho-
motor speed performance; Digit Span Forward and Back-
ward for attention and working memory; Finger Tapping
Test for motor performance and lastly verbal fluency was
assessed with the Category Naming Test. The Karnofsky
Performance tested for functional performance. A score
of 10 or fewer points on the IHDS indicates that an indi-
vidual has an increased likelihood of cognitive impair-
ment associated with HIV infection. All these
assessments were used to assign a Memorial Sloan Ket-
tering (MSK) dementia stage of 0, 0.5, or ≥1 [22,23].
Details about the instruments appear in earlier publica-
tions [19,24].
Data analysis
Comparisons were made between the HIV-positive and
HIV-negative group as detailed below. All analyses were
conducted using SAS statistical software package (SAS
Institute, Carey, NC). Statistical significance was set at a
Type I error of 0.05.
Baseline prevalence
Baseline prevalence of depression symptomatology and
cognitive impairment among HIV-positive and HIV-neg-
ative individuals was estimated as the ratio of the number
of individuals meeting screening criteria on either the
CES-D or the IHDS to the number of individuals com-
pleting the respective screening instrument at baseline.
Chi square and Fisher's exact tests were used to compare
the MSK score for cognition and the CES-D score for
depressive symptoms. A 95% confidence interval (CI) for
this prevalence estimate was calculated. Similarly, the
proportion of HIV-positive and HIV-negative individuals
with dual prevalence of depressive symptomatology and
cognitive impairment was estimated.
These estimates were compared using logistic regres-
sion methods with prevalence as the dependent measure
and HIV status as the independent measure to determine
the likelihood of depression symptoms given HIV infec-
tion. Baseline characteristics of age and gender were
included in the predictive model, as there were significant
differences on these factors between the two groups.
HAART impact on depression symptomatology
Individual participants were classified as having depres-
sion symptoms, cognitive impairment, or both at baseline
and at 3- and 6-months follow-up. Differences in the like-
lihood of these conditions were modelled using a
repeated measures logistic regression model. The model
was adjusted for baseline characteristics of age, gender
and HIV status. The potential for interaction between
HIV status and follow-up time was tested.
Results
The HIV-positive and HIV-negative cohorts had a com-
parable mean age (34.2 years versus 30.3 years) but the
HIV-positive individuals were more likely to be female
(73% versus 40%) and had lower baseline Karnofsky Per-
formance Scale scores (mean 84 SD 8.5) compared to the
HIV-negative individuals (mean 98 SD 4.1). The read/
write language variables at baseline revealed that of the
HIV-negative controls, 25/25 (100%) could read and 24/
25 (96%) could write. For the HIV-positive participants,
92/103(89.3%) could read and 84/103 (81.5%) could write.
These differences in reading and writing were not signifi-
cant for reading (p = 0.082), but were for writing (p =
0.039) using Fisher's exact test. Baseline HIV RNA (mean,
SD) for individuals with CES-D ≤ 16 was 239,720
(267,034) while for CESD of ≥ 16 it was 241,636
(240,054). The difference was not significant between the
two groups (p = 0.970). The mean CD4 cell count for the
HIV positive group was 130 cells/ul at baseline.
Prevalence of depression symptoms
Based on CES-D scores, 55/102 HIV-positive individuals
were identified with depression symptoms at baseline i.e.
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symptoms was estimated to be 53.9% (95% CI 44.1%,
63.8%). Similarly, 7/25 (28%) HIV-negative individuals
were identified with depression symptoms (95% CI 10.4%,
45.6%). Adjusting for differences in age and gender, the
likelihood of depression symptoms was significantly
higher among HIV-positive individuals compared to
HIV-negative individuals (OR 2.86, 95% CI: 1.03, 7.95, p =
0.044).
Prevalence of cognitive impairment
Based on IHDS scores, 70/102 HIV-positive individuals
were identified with cognitive impairment at baseline
(Table 1). Prevalence of cognitive impairment was esti-
mated to be 68.6% (95% CI 59.6%, 77.6%). Among HIV-
negative individuals, 4/25 (16%) were identified with cog-
nitive impairment (95% CI 1.6%, 30.4%). There was a
greater trend for improvement on the neuropsychological
battery tests among the HIV-positive subjects but the
only significant change was in Color Trails 2 test (p =
0.020) after adjusting for differences in sex. There was no
association between clinical MSK score and depression
symptoms (p = 0.310) at baseline. After adjusting for age
and gender, the likelihood of cognitive impairment was
significantly higher among HIV-positive individuals com-
pared to HIV-negative individuals (OR 8.88, 95% CI 2.64,
29.89, p < 0.001).
Dual prevalence
Based on CES-D and IHDS scores, 40/102 HIV-positive
individuals were identified with both depression symp-
toms and cognitive impairment (Table 1). Dual preva-
lence of these conditions was estimated to be 39.2% (95%
CI 29.7%, 48.7%). Among HIV-negative individuals 1/25
(4%) was identified with both depression symptoms and
cognitive impairment (95% CI -3.6%, 11.7%). Adjusting
for age and gender, the likelihood of both depression
symptoms and cognitive impairment among HIV-posi-
tive individuals was significantly higher in this group
compared to HIV-negative individuals (OR 13.96, 95% CI
1.74, 111.73, p = 0.013).
Longitudinal follow-up
The retention rate of study participants in the study was
fairly good. Of the HIV-negative controls, 23/25 (92%)
Table 1: Demographic and Clinical Characteristics of the HIV-positive and HIV-negative individuals.
Characteristic HIV Positive N = 102 HIV Negative N = 25 p-value1
Age, years (mean, SD) 34.2 (6.23) 30.3 (3.99) .004
Female, n (%) 74 (72.6%) 10 (40.0%) .004
Education, years (mean, SD) 9.1 (4.3) 10.4 (4.2) .207
CD4 cell count (mean, SD) 130 (69.5) N/A .654
Plasma HIV RNA, log-10 copies/mL (mean, SD) 4.9 (0.87) N/A .672
CES-D score (mean, SD) 18.1 (11.4) 9.1 (9.0) < .001
Karnofsky Score 84 (8.5) 98 (4.1) 0.001
Prevalence of depression symptoms
Baseline (HIV+ = 102 HIV- = 25) 55 (53.9%) 7 (28.0%) .021
3-month (HIV+ = 95 HIV- = 23) 34 (36.0%) 3 (13.0%) .008
6-month (HIV+ = 93 HIV- = 21) 28 (30.0%) 5 (24.0%) .206
IHDS score (mean, SD) 9.44 (1.8) 11.10 (0.8) < .001
Prevalence of cognitive impairment
Baseline -do- 70 (68.6%) 4 (16.0%) < .0012
3-month -do- 34 (35.8%) 5 (21.7%)
6-month -do- 28 (30.1%) 9 (42.8%)
Dual prevalence of depression and cognitive impairment
Baseline -do- 40 (39.2%) 1 (4.0%) .0132
3-month -do- 34 (35.8%) 1 (4.0%)
6-month -do- 28 (30.1%) 2 (9.5%)
1Differences between HIV-positive and HIV-negative individuals were made using Student t-test (continuous measures) or Fisher's exact test 
(binary measures) unless otherwise noted.
2Differences in prevalence measures were assessed using logistic regression, adjusting for age and gender.
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for the third visit. Of the HIV-positive participants, 95/
103(92%) returned for the second visit and 93/103 (90%)
returned for the third visit.
Significant interaction terms indicate that HIV-positive
patients experience a different long-term course in out-
come compared to HIV-negative individuals. HIV-posi-
tive individuals experienced a significant decrease in the
prevalence of depression symptomatology (p = 0.026),
cognitive impairment (p < 0.001), and dual prevalence of
these two conditions (p = 0.004) compared to HIV-nega-
tive individuals, see figure 1. At the 6 month follow up
time point the difference in CES-D score was not statisti-
cally significant between the HIV positive and the HIV
negative group however, the cognitive impairment was
higher for the HIV-negative group. In addition to experi-
encing this decline in prevalence, mean scores on the
CES-D and the IHDS decreased significantly among
HIV-positive individuals compared to HIV-negative indi-
viduals (p = 0.003 and p < 0.001, respectively). Though
the mean CD4 increased from 129 at baseline to 272
cells/ul at 6 months (p = 0.010), we noted there was no
association between increasing CD4 cell count and
decreasing CES-D score (p = 0.168) over the study
period. Similarly, there was a marked reduction in log10
plasma HIV RNA of the HIV-positive group from 4.92
log10 copies/mL to 2.53 log10 copies/mL by the 6 months
review. Using a repeated measures analysis of variance,
this was a statistically significant reduction (p < 0.001).
Discussion
We aimed to estimate the prevalence of depression symp-
tomatology and cognitive impairment among HIV-posi-
tive individuals through a comparative study. We have
shown that the presence of the depressive symptomatol-
ogy and cognitive impairment was higher at baseline
among HIV-positive individuals at risk of cognitive
impairment compared to HIV-negative individuals. The
scores generated on the cognitive tests in both groups of
individuals were not biased by literacy level as the sample
had a high literacy rate. Both the depression symptoma-
tology and cognitive impairment improved after initia-
tion of highly active antiretroviral therapy.
In the general population 20% of individuals are
expected to have abnormal scores on the CES-D [21].
This instrument has been used in a number of African
HIV populations and found to be valid [12,11]. The DSM-
IV acknowledges that psychiatric conditions including
depression can exhibit as a symptom a mild degree of
cognitive impairment. On the other hand, depression can
also be a major symptom of cognitive impairment and is
estimated to be present in 40-50% of patients with
dementia hence posing a diagnostic challenge [17,25].
Indeed, in our current study, we found a high rate of dual
prevalence for both conditions.
Individuals with a high viral load have been shown to
have more symptoms for depression [26]. As individuals
improved immunologically with an increase in the CD4
count, there was a decrease in the symptoms of cognitive
impairment and depression. However, surprising to us
was the persistence of depression symptomatology well
above the cut off score in a number of the study partici-
pants suggesting that the two conditions i.e. cognitive
impairment and depressive symptoms can be distinct and
should be treated appropriately for good treatment out-
come. By the end of the follow up period, individuals in
the HIV positive group had a higher prevalence of the
depressive symptomatology; this may have been as a
result of loss to follow up in the study group. However
loss to follow up was insignificant and therefore it is
unlikely that the difference between the groups is totally
attributable to the difference in the attrition rates of the
HIV-positive and HIV-negative groups.
Persisting depressive symptomatology can be a great
contributor to disability in affected individuals[2,3]. This
may have implications on the general well-being of the
individual as often the depression is somatized and is
usually missed in primary health care and hence is left
untreated [27]. Such individuals may keep returning for
clinic reviews even when they may not have done so had
their depression been detected and treated early.
The HIV-positive subjects in our study were represen-
tative of the demographics of HIV infection in Uganda.
The majority of HIV infected individuals seen in HIV/
AIDS care are women, a group that at the same time
tends to contribute more to individuals that suffer from
depression as has been shown by previous studies
[3,5,12]. Another study conducted by Kaharuza and other
[12] showed the prevalence of depression symptomatol-
ogy to be 43% which is comparable with our study find-
ings. However in that study the cut off of 23/60 on the
CES-D was considered as a case of depression. Whereas
in that study the presence of a high score of symptoms
was considered indicative of depression, our study used a
cut off of > 16 to indicate depression symptomatology on
the CES-D. The cut off of 16 for the CES-D to define
depression symptomatology has been used frequently in
other research studies [11,28]. Other studies found differ-
ent rates ranging from 14% to 35%, probably as a result of
a different methodology and the use of different diagnos-
tic instruments [10,11].
Depression greatly affects the functioning of an individ-
ual [3]. This can be made worse by lack of detection and
non-treatment, more so in individuals that may be cogni-
tively impaired. Such a situation works against successful
treatment of HIV infected patients, making it imperative
to diagnose and effectively treat depression to improve
Nakasujja et al. BMC Psychiatry 2010, 10:44
http://www.biomedcentral.com/1471-244X/10/44
Page 6 of 7Figure 1 Mean CES-D scores among HIV-negative and HIV-positive individuals. The depressive symptoms measured with CES-D show a decline 
in the average score over the study period. This decline in symptoms was significant in the HIV-positive individuals p = 0.003 but not among the HIV-
negative individuals p = 0.434.
 
the outcome of antiretroviral therapy. In this study the
symptomatology for depression kept on decreasing with
time with an inverse increase in the functionality of the
individual. Depression as a mood disorder can be a self
limiting condition. However given the burden of disease
the condition brings about, it should be treated whenever
it is detected in an individual.
The observed decrease in the CES-D scores may be a
result of the improving health of the individuals brought
about by antiretroviral therapy. However, even though
the CD4 count increased in these study patients they also
had a persistently high average CES-D score over the
study period. This finding emphasizes the fact that
depression symptomatology does not fully resolve with
antiretroviral therapy. Therefore, appropriate treatment
with antidepressant therapy should be instituted for such
patients. Whereas the CES-D-scale is only a screening
instrument that may pick up symptoms of depression, the
individuals that remained with depressive symptomatol-
ogy (30%) could possibly be diagnosed as having a major
depression disorder were they to be subjected to DSM-IV
research diagnostic criteria. Indeed such patients require
antidepressant medication that, unfortunately they were
not receiving.
This study was not without limitations. The compara-
tive group included only 25 HIV-negative individuals for
statistical and practical reasons. Practically it was more
difficult to recruit the HIV-negative individuals and
retain them in the follow-up. They had no reason to
return as they had no ailment or need for medication.
Secondly, because these individuals are neurologically
normal, they, as a group, exhibit less variability on the
outcome measures. Therefore, we needed to enroll and
follow a smaller number. However the sample recruited
in both the HIV-positive and HIV-negative groups was
sufficient to show statistical difference in the outcome
measures.
Conclusions
Depression symptomatology is distinct and common
among cognitively impaired HIV patients. A large num-
ber of individuals that are HIV infected in Sub-Saharan
Africa, do not receive care. It is important therefore, that
those who attend HIV care are screened for depression
symptoms and cognitive dysfunction. This would make it
possible to manage both conditions appropriately so as to
improve patient outcomes.
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